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T he major perinatal brain lesions associated with cerebral palsy and cognitive impairment are periventricular white matter damage and cortical-subcortical lesions, observed mainly in preterm and term infants, respectively (1, 2) . A crucial step for the implementation of neuroprotective therapies is the rapid detection of neonates at risk. Despite this urgent need, no appropriate and easily detectable biomarkers for perinatal injury are currently available.
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in multiple processes during development and in adulthood (3) (4) (5) , including perinatal hypoxia-ischemia (HI) and white matter damage in human neonates. Recent studies in adult MMP-9 knockout mice have demonstrated the key role played by this metalloproteinase in the pathophysiology of traumatic and hypoxic-ischemic (HI) brain injury (6) . Concordantly, MMP-9 has been shown to have deleterious effects in the immature brain after HI injury (7) . Several of these studies demonstrated a significant increase in MMP-9 expression in the central nervous system within the first 24 h after the insult. MMP-9 also has long-term beneficial effects on neurovascular remodeling and behavioral recovery after stroke in adult rats (8, 9) . In the adult rat central nervous system, elevated TIMP-1 expression levels may play a neuroprotective role after kainate-induced excitotoxic seizures (10) , and gene transfer of TIMP-1 and 2 protects against global cerebral ischemia in mice (11, 12) . The fact that MMPs and TIMPs are secreted proteins that can easily be measured in bodily fluids including peripheral blood (13) highlights their potential as biomarkers for brain injury. Indeed, MMP-9 has already been evaluated as a biomarker for acute ischemic stroke in adult patients (14) . However, their usefulness in neonates has not so far been demonstrated.
As a first step in the validation of MMPs and/or TIMPs as biomarkers for perinatal brain injury, we used a model of HI injury in postnatal day 9 (P9) mice (which mimics the gray matter lesions observed in human neonatal encephalopathy (NE)) (15) , to study the correlation between plasma levels and brain levels of these molecules. We evaluated the specificity of these molecules for HI damage by measuring MMP and TIMP levels in two other conditions: ibotenate-induced excitotoxic lesions in P5 mice (which mimic periventricular white matter damage in preterm infants) (16) , and lipopolysaccharide (LPS) injections (which mimic bacterial infection/inflammation in addition to sensitizing the brain to HI insults) (17) . Over and above the mechanistic insights yielded by the use of animal models, we obtained information were not different from the levels in controls at any time point. The gelatinolytic activity of neocortical MMP-9 after ibotenate injection in P9 C57BL/6 mice was also negligible at all time points studied, and plasma MMP-9 levels revealed no difference from those of controls (data not shown). Neocortical TIMP-1 protein levels ( Figure 3c ) were briefly but significantly higher 24 h after ibotenate injection in P5 Swiss mice as compared to control mice. No increase was observed in the plasma protein levels (Figure 3d) . At all other time points, TIMP-1 protein levels in ibotenate-treated and control mice were comparable.
Levels of MMPs and TIMPs in Plasma and Neocortices of hypoxic and LPS-exposed Mice
There was no increase in neocortical gelatinolytic activity or in levels of MMP-9 (Figure 3a) , MMP-2 (data not shown), or TIMP-1 (Figure 3c , and controls (C; black bars). Bars represent mean concentrations ± SeM. *P < 0.001; **P < 0.01; §P < 0.05; two-way analysis of variance with Bonferroni post hoc test. a,b: MMP-9 concentrations in (a) the neocortex and (b) plasma at various time points. the effect of HI was extremely significant at 24 h (P < 0.001) and 3 days (P < 0.01) in the neocortex, and was significant at 1 h (P < 0.001), 3 h (P < 0.01), 6 h (P < 0.05), and 3 days (P < 0.001) in plasma, relative to C mice. Neither H nor Ibo affected MMP-9 protein levels. c,d: tIMP-1 concentrations in (c) the neocortex and (d) plasma at various time points. the effect of HI was extremely significant at 24 h (P < 0.001) and 3 days (P < 0.01) in the neocortex, and from 1 h up to 3 days (P < 0.001) in plasma, relative to C mice. the effect of an excitotoxic (Ibo) injury on neocortical tIMP-1 levels was extremely significant at 24 h only (P < 0.001), whereas plasma levels were unchanged. H did not affect tIMP-1 protein levels. MMP, matrix metalloproteinase; tIMP, tissue inhibitor of metalloproteinase. 
Levels of MMPs and TIMPs in Human Plasma Samples
Control group. MMP-2, TIMP-1, and TIMP-2 were easily detected at all ages using enzyme-linked immunosorbent assay; age and gender did not affect the results (data not shown). Mean values, SD, and range for MMP-2, MMP-9, TIMP-1, and TIMP-2 levels in plasma are shown in Table 1 . Plasma MMP-9 levels were significantly lower in 25-to 27-week-old infants than in those of higher gestational age (P ≤ 0.05; see Table 1 ). For this reason, and to exclude any effect of extreme prematurity not pertinent to this study, only data from preterm infants of gestational age ≥34 weeks were analyzed as controls ( Table 1) . Table 2 ) MMP-2 and TIMP-2 levels were not influenced by pathological conditions (data not shown). However, MMP-9 levels were significantly increased in the NE group (mean ± SD: 342 ± 312 ng; median: 189 ng; range = 6-1,313 ng) as compared to controls; the wide range of values reflected the fact that the group included Sarnat stage 1 (S1) infants (not different from controls) along with S2 and S3 infants (Figure 4a ).
NE group. (
No differences in MMP-9 levels were observed between NE patients with a favorable outcome and those with an unfavorable outcome (Figure 4a) . TIMP-1 levels were significantly higher in NE patients than in controls (Figure 4b ) (570 ± 382 ng; range = 107-1,551 ng), mainly because of the presence of S2 infants in the group (Figure 4b) ; also, these levels were higher in NE patients with a favorable outcome than in those with an unfavorable outcome (Figure 4b) . Infectious group. (Table 3 ) Systemic infection did not influence MMP-2 (data not shown), MMP-9 (Figure 4a) , TIMP-1 (Figure 4b) , or TIMP-2 protein levels (data not shown).
DISCUSSION
This study demonstrates not only that MMP-9 and TIMP-1 levels are elevated in both NE infants and in neonatal mice with HI brain injury, but also, remarkably, that these changes are measurable in plasma at an early time point after the insult. These results are corroborated by early elevated MMP-9 and TIMP-1 levels in the neocortices of HI mice. Of interest, in human infants, MMP-9 plasma levels were correlated with the severity of NE, whereas TIMP-1 plasma levels were predictive of long-term sequelae. The significant increase in plasma MMP-9 levels within the first 6 h after birth is of critical importance in selecting newborns at high risk for neurological damage, or those most likely to benefit from neuroprotection. MMP-9 levels after 6 h after birth may be less informative and may include false-negative results. Articles Bednarek et al.
Of note, none of the other pathological conditions studiedexcitotoxic lesions, hypoxia, or LPS-induced inflammationaffected MMP-9 and TIMP-1 protein levels in mouse brain or plasma, although the duration of the experiment was sufficient for MMP-9 and TIMP-1 activation in these groups; in contrast, MMP-9 levels in HI mice increased as early as 1 h after the insult. Excitotoxic and inflammatory processes are involved in both the early phase of brain ischemia and the regulation of MMP expression. However, one cannot rule out the possibility that the severity of tissue damage is a factor contributing to the increase in MMP-9 and TIMP-1 expression in HI mice, given that brain lesions are known to be more severe from a histological viewpoint in the HI model than in the excitotoxin models (7, 18) .
Similarly, although we used two different strains of mice (Swiss for ibotenate and C57Bl/6 for HI), it is unlikely that differences in the strain used greatly influenced our results, 
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because we have previously shown that the ontogeny of MMP-2, MMP-9, TIMP-1, and TIMP-2 is strain-independent (19) . Differences in the ages of the two sets of mice (P9 for HI and P5 for ibotenate) can also be eliminated as a factor, because ibotenate injected at age P9 in C57BL/6 mice did not increase plasma MMP-9 levels. In fact, under physiological conditions, MMP-9 is undetectable in the postnatal mouse brain (19) . Of interest, hypoxia by itself did not affect levels of MMP-9 and TIMP-1 in the brain, suggesting that ischemia is the key contributor to the observed increases in MMP-9 and TIMP-1 expressions.
In the study in human newborns also, those with a systemic infection did not display any increase in MMP-9 or TIMP-1 levels relative to the controls, suggesting that systemic infection associated with neonatal NE does not interfere with the interpretation of plasma MMP-9 and TIMP-1 measurements, unlike other biomarkers such as lactates or cytokines that are also upregulated (20) . Another advantage of measuring MMP-9 and TIMP-1 levels in plasma is the relative ease of access when compared with the collection of cerebrospinal fluid or urine samples that are generally required for other prognostic biomarkers.
The levels of MMP-9 and TIMP-1 in the neocortices and plasma of mice and in the plasma of human neonates are closely matched over time, suggesting that MMP-9 activity is tightly controlled by its endogenous inhibitor, TIMP-1. This balance between the two molecules is thought to reduce brain damage in HI events by protecting the blood-brain barrier (7) . MMP inhibition provides neuroprotection against HI in the developing brain (21) . A neuroprotective role for TIMP-1 in excitotoxic damage and ischemia has been previously proposed (10, 11, 22) . In addition, TIMP-1 levels have recently been shown to be correlated with stroke outcome in adult humans (23) .
When comparing the profiles of MMP-9 and TIMP-1 over time in the neocortex and plasma, it appears that the levels of both molecules increase in the plasma before they increase in the neocortex (1 h vs. 24 h after the insult) and return to basal values earlier in plasma than in the neocortex (3 days vs. 5 days after the insult), suggesting that circulating MMP-9 and TIMP-1 do not originate in the brain. Although our data do not allow us to discriminate between peripheral origin and diffusion from the lesion site, one could speculate that early increases in plasma MMP-9 and TIMP-1 have a systemic source related to multiorgan injury after moderate/severe HI. The release of MMP-9 by peripheral blood leukocytes, known to be activated in neonatal asphyxia, could contribute to this elevation (24) . The second plasma peak at 24 h in mice and human infants could be Articles Bednarek et al.
the result of passive diffusion of MMP-9 and TIMP-1 produced in the brain, possibly by the death of neural cells as in the case of global ischemic injury (9) . Alternatively, blood-brain barrier breakdown and the inflammatory response, involved early in focal injury, could lead to an increase not only in MMP-9 but also in MMP-2, MMP-3, and TIMP-3. However, reports regarding MMP-2 are often contradictory (4, 22, 25, 26) , and we therefore preferred to focus on the more reliable marker, MMP-9 (9). The second peak of MMP-9 in the brain might also reflect the secondary phase of energy failure induced by HI (27) . A second but considerably delayed peak of MMP-9 activity in the brain has also been seen by others (26) . Despite their uncertain origin, circulating MMP-9 and TIMP-1 levels are potential biomarkers of NE severity. The levels and significance of MMP-9 and MMP-2 have been previously evaluated in stroke in adult patients (14, 28) . In adults, high plasma MMP-9 levels have been associated with the occurrence of early hemorrhagic complications after thrombolysis (28) and early deterioration during cerebral ischemia (29) . However, to our knowledge, only one study has explored plasma levels of MMP-9 in perinatal asphyxia: MMP-9 and TIMP-1 levels measured on the day of birth in asphyxiated infants with sequelae were significantly higher than in infants with a favorable outcome or in control patients (30) . The discrepancy between the results of that study and ours could be attributable to the low number of patients in the former, or the timing of blood sampling in that study, which was reported as occurring on the day of birth, but no details were mentioned. Although NE infants with an S1 in our study were not significantly different from controls in terms of MMP-9 plasma levels, those with higher Sarnat stages had significantly higher MMP-9 levels, in keeping with a correlation between levels of this protein and severity of brain damage. In contrast, plasma TIMP-1 levels showed a different pattern, being higher in S2 infants than in S1 or S3 infants. Although it is easy to dismiss low TIMP-1 levels in S1 infants as reflecting a lack of severe lesions, as suggested by their low MMP-9 levels, it could well be that the neuroprotective effects of TIMP-1 in the S2 and S3 groups are responsible for a more favorable outcome in the former, and vice versa.
Remarkably, plasma MMP-9 levels in the NE infants in our study were higher (441.7 ± 91.5 ng/ml) than those observed in adult stroke patients (147.1 ± 118.6 ng/ml) (30) . One possible explanation is that the mechanism underlying perinatal HI events is associated with more global effects on different organs (e.g., umbilical cord compression/placental abruption) than is the ischemic mechanism (i.e., blood clot), which is restricted to the brain in adult stroke.
This study provides preliminary evidence that MMP-9 and TIMP-1 could act as early biomarkers of brain damage in NE, and offers new avenues for research that could benefit human full-term newborns. However, before the use of these proteins as biomarkers can be validated, more steps are required: (i) identifying their initial source of secretion, (ii) understanding the etiology of the biphasic secretion of MMP-9, and (iii) evaluating their specificity and sensitivity and correlating their concentration levels with the degree and type of brain damage in humans and in animal models.
MetHODS
The study in human newborns was approved by the Reims Hospital ethics committee. Written informed consent was obtained from parents/ legal representatives of all patients enrolled in this study. Experimental protocols in animals were approved by the Institutional Animal Care Bars represent mean protein concentration ± SeM. *P < 0.05; **P < 0.01; patient groups (white bars) vs. controls (black bar); analysis of variance and Bonferroni's multiple comparison test. (a) MMP-9 protein levels in the plasma of control (black bar), Ne, Ne differentiated according to Sarnat stage (S1, S2, S3) or according to favorable/unfavorable outcome following Ne, and infected infants. Apart from the S1 group, MMP-9 levels in the plasma of all Ne infants were significantly higher than in controls, regardless of Sarnat stage or outcome. (b) tIMP-1 protein levels in the plasma of control (black bar), Ne, Ne differentiated according to Sarnat stage (S1, S2, S3), or according to favorable or unfavorable outcome following Ne, and infected infants. tIMP-1 levels were significantly higher in the plasma for all Ne infants and those with S2 Ne, as well as those with a favorable outcome. MMP, matrix metalloproteinase; tIMP, tissue inhibitor of metalloproteinase; Ne, neonatal encephalopathy. 
